

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 12, 2019
PDL Changes Effective Date: April 1, 2019



The following changes will be made to the Preferred Drug List (PDL), effective April 1, 2019, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to <http://www.medicaid.ms.gov/providers/pharmacy/preferred-druglist/.NEW>

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Antibiotics (GI)	FIRVANQ (vancomycin)
Antipsychotics - Injectable, Atypical	PERSERIS (risperidone)
Antivirals, Anti-Influenza Agents	oseltamivir
Antivirals, Anti-Influenza Agents	TAMIFLU (oseltamivir)
Miscellaneous Brand/Generic	hydroxyurea
Platelet Stimulating Agents	PROMACTA (eltrombopag olamine)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Acne Agents, Retnoids	ALTRENO (tretinoin)
Acne Agents, Retnoids	PLIXDA (adapalene)
Analgesics, Narcotic – Short Acting	ROXYBOND (oxycodone)
Analgesics/Anesthetics (Topical)	ZTlido (lidocaine)
Androgenic Agents	XYOSTED (testosterone enanthate)
Anticonvulsants, Adjuvants	EPIDIOLEX (cannabidiol)
Anticonvulsants, Adjuvants	SYMPAZAN (clobazam)
Antimigraine Agents, Calcitonin Gene-Related Peptide Inhibitor	AJOVY (fremanezumab-vfrm)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 12, 2019
PDL Changes Effective Date: April 1, 2019



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Antimigraine Agents, Calcitonin Gene-Related Peptide Inhibitor	EMGALITY (galcanezumab-gnlm)
Antineoplastics – Selected Systemic Enzyme Inhibitors	BRAFTOVI (encorafenib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	LORBRENA (lorlatinib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	MEKTOVI (binimetnib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	TALZENNA (talazoparib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	TIBSOVO (ivosidenib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	VIZIMPRO (dacomitinib)
Antiretrovirals, Single Tablet Regimens	DELSTRIGO (doravirine/lamivudine/tenofovir)
Antiretrovirals, Single Tablet Regimens	SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir)
Antiretrovirals, NNRTIs	PIFELTRO (doravirine)
Antiretrovirals, Combination Products – Nucleoside & Nucleotide Analogs & Non-Nucleoside RTIs	DELSTRIGO (doravirine/lamivudine/tenofovir)
Antivirals, Anti-Influenza Agents	FLUMADINE (rimantadine)
Antivirals, Anti-Influenza Agents	RAPIVAB (peramivir)
Antivirals, Anti-Influenza Agents	RELENZA (zanamivir)
Antivirals, Anti-Influenza Agents	rimantadine
Antivirals, Anti-Influenza Agents	XOFLUZA (baloxavir marboxil)
Beta Blockers, Antianginals & Sinus Node Agents	KAPSPARGO SPRINKLES (metoprolol)
Colony Stimulating Factors	NIVESTYM (filgrastim-aafi)
Cytokine & Cam Antagonists	ILUMYA (tildrakizumab)
Cytokine & Cam Antagonists	OLUMIANT (baricitinib)
Hereditary Angioedema	TAKHZYRO (lanadelumab-flyo)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 12, 2019
PDL Changes Effective Date: April 1, 2019



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Lipotropics, Statins	ZYPITAMAG (pitavastatin)
Miscellaneous Brand/Generic	SIKLOS (hydroxyurea)
Ophthalmic Anti-Inflammatories	INVELTYS (loteprednol etabonate)
Ophthalmic, Glaucoma Agents	XELPROS (lantanoprost)
Opiate Dependence Treatments	LUCEMYRA (lofexidine)
Platelet Stimulating Agents	DOPTELET (avatrombopag maleate)
Platelet Stimulating Agents	MULPLETA (lusutrombopag)
Platelet Stimulating Agents	NPLATE (romiplostim)
Platelet Stimulating Agents	RITUXAN (rituximab)
Platelet Stimulating Agents	TAVALISSE (fostamatinib disodium)